כניסה 
עקבו אחרינו בפייסבוק הבדלים בין גרסאות בדף "טבלאות רגישויות מבית החולים שערי צדק - תרביות שתן - Shaare zedek medical center antibiotic sensitivity table - urine cultures"
מתוך ויקירפואה
| שורה 129: | שורה 129: | ||
{|dir="ltr" border="1" cellpadding="4" | {|dir="ltr" border="1" cellpadding="4" | ||
| | | | ||
| − | !≤48 hrs in hospital{{כ}}{{הערה|שם= | + | !≤48 hrs in hospital{{כ}}{{הערה|שם=הערה2|continues to be tested}} |
| − | !>48 hours in hospital{{הערה|שם= | + | !>48 hours in hospital{{הערה|שם=הערה2}} |
| + | |- | ||
| + | |colspan="3"|Penicillins | ||
| + | |- | ||
| + | | Mezlocillin{{כ}}{{הערה|שם=הערה2}} || 77 || 73 | ||
| + | |- | ||
| + | | Tazocin || 92 || 88 | ||
| + | |- | ||
| + | |colspan="3"| Cephalosporins | ||
| + | |- | ||
| + | | Ceftazidime || 92 || 89 | ||
| + | |- | ||
| + | | Cefepime{{כ}}{{הערה|1=tested until 2006 }}||95||94 | ||
|- | |- | ||
|colspan="3"|Carbapenems | |colspan="3"|Carbapenems | ||
| שורה 136: | שורה 148: | ||
| Imipenem || 94 || 91 | | Imipenem || 94 || 91 | ||
|- | |- | ||
| − | | | + | | Meropenem{{כ}}{{הערה|1=tested since 2006}} || 94 || 93 |
|- | |- | ||
|colspan="3"|Aminoglycosides | |colspan="3"|Aminoglycosides | ||
גרסה מ־08:53, 26 בספטמבר 2013
| שם הספר: שימוש מושכל באנטיביוטיקה ונהלים למניעת זיהומים | |
|---|---|
| |
| שם המחבר | פרופ' עמוס ינון, פרופ' יחיאל שלזינגר, דר' דוד רווה |
| שם הפרק | טבלאות רגישויות מבית החולים שערי צדק - תרביות שתן - Shaare zedek medical center antibiotic sensitivity table - urine cultures |
| מוציא לאור |  |
| מועד הוצאה | תשע"א – 2010 |
| מספר עמודים | 196 |
| הקדשה | ספר זה מוקדש לפרופ' חיים הרשקו בהוקרה עמוקה |
Table 12: Urine cultures
Table 12a: Urine cultures, main isolates, by source of patients (2001-2008)
| Isolated organism | ≤48 hours in hospital
N=21833 |
>48 hours in hospital
N=9823 |
p |
|---|---|---|---|
| Acinetobacter | 237 (1) | 585 (6) | <0.001 |
| Enterobacteriaceae (total) | 15323 (70) | 5397 (55) | <0.001 |
| Citrobacter koserii | 499 (2) | 174 (2) | |
| Enterobacter cloacae | 411 (2) | 312 (3) | |
| E.coli | 8853 (40) | 1927 (20) | <0.001 |
| Klebsiella pneumoniae | 2132 (10) | 1371 (14) | <0.001 |
| Morganella morganii | 360 (2) | 192 (2) | |
| Proteus mirabilis | 1640 (7) | 762 (8) | <0.01 |
| Providencia stuartii | 196 | 131 | |
| Serratia marcescens | 77 | 52 | |
| Enterococcus sp. | 2467 (11) | 1833 (19) | <0.001 |
| Pseudomonas aeruginosa | 1404 (6) | 1263 (13) | <0.001 |
| Staphylococcus aureus | 394 (1) | 107 (1) | |
| Staphylococcus epidermidis | 686 (3) | 309 (3) | |
| Streptococcus | 707 (3) | 123 (1) | <0.001 |
| Group A | 22 | 4 | |
| Group B | 394 (2) | 50 (0.5) | <0.001 |
| Group D | 90 | 24 | |
| Group G | 12 | 3 | |
| S.viridans | 122 | 15 |
Table 12b: Antimicrobial susceptibilities (%) of Enterobacteriaceae isolated from urine cultures, 2000-2008
|
N |
≤48 hrs in hospital[1]
15316 |
>48 hours in hospital[1]
5397 |
|---|---|---|
| Penicillins | ||
| Augmentin | 65 | 51 |
| Tazocin | 92 | 82 |
| Cephalosporins | ||
| Cefazolin | 63 | 43 |
| Cefuroxime | 76 | 56 |
| Ceftriaxone | 84 | 66 |
| Ceftazidime | 84 | 67 |
| Cefepime | 86 | 69 |
| Carbapenems | ||
| Ertapenem | 99 | 96 |
| Imipenem | 99 | 98 |
| Aminoglycosides | ||
| Gentamicin | 85 | 69 |
| Amikacin | 98 | 94 |
| Other | ||
| Chloramph | 78 | 62 |
| Cotrimoxazole | 62 | 52 |
| Ciprofloxacin[2] | 76 | 60 |
| Colistin | 84 | 77 |
| Nitrofurantoin | 70 | 52 |
| ESBL-positive[3] | 15 | 32 |
Table 12c: Antimicrobial susceptibilities (%) of Pseudomonas aeruginosa isolated from urine cultures, 2001-2008
| ≤48 hrs in hospital[4] | >48 hours in hospital[4] | |
|---|---|---|
| Penicillins | ||
| Mezlocillin[4] | 77 | 73 |
| Tazocin | 92 | 88 |
| Cephalosporins | ||
| Ceftazidime | 92 | 89 |
| Cefepime[5] | 95 | 94 |
| Carbapenems | ||
| Imipenem | 94 | 91 |
| Meropenem[6] | 94 | 93 |
| Aminoglycosides | ||
| Gentamicin | 84 | 81 |
| Amikacin | 94 | 93 |
| Other | ||
| Ciprofloxacin | 73 | 69 |
| Colistin | 100 | 100 |
הערות שוליים
- ↑ 1.0 1.1 Differences in rates of susceptibility between community and hospital acquired strains were significant for all antimicrobials (p<0.001).
- ↑ No significant changes in susceptibility % were noted over the study period.
- ↑ ESBL: extended spectrum beta-lactamase
- ↑ 4.0 4.1 4.2 continues to be tested
- ↑ tested until 2006
- ↑ tested since 2006
ביבליוגרפיה
- Raveh D, Rudensky B, Huerta M, Aviv Y, Yinnon AM. Use of time-trend analysis in the design of empirical antimicrobial treatment of urinary tract infection. Eur J Clin Microbiol Infect Dis 2003; 22(3):158-64.
- Raveh D, Rosenzweig I, Rudensky B, Yinnon AM. Prospective, case control study to determine risk factors for community-acquired urinary tract infection due to Pseudomonas aeruginosa or Enterococcus. Eur J Clin Microbiol Infect Dis 2006; 25: 331-334.